Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Determine the SP 500 fund with the best 15-year return and understand factors driving the outperformance over this horizon.
28,427 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
A 66-year-old with only $10k saved confronts retirement math as housing costs loom. Experts say disciplined saving, d...
CoreWeave's backlog booming has caught the eye of investors eyeing AI infrastructure. This piece breaks down whether ...
Bitcoin’s iran rally faces a fresh test as macro signals from oil, equities, and Japanese policy converge. Markets we...
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
Analysts are watching every cue as Apple navigates leadership shifts and growth bets. This article breaks down what a...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Oracle is leaning into AI infrastructure with its database expertise, cloud platform, and data-center plans. This art...
Li Auto's 2026 earnings outlook hinges on shipments, margins, and smart capital allocation. This deep dive breaks dow...
Broadcom has surged after April began, but the big question remains: is the rally sustainable? This guide breaks down...
Solana (sol) hits 2026 high in headlines as sentiment worsens, yet new on-chain activity and a fresh technical setup ...
Peter Thiel and Founders Fund have fully exited ETHZilla, dissolving a high-profile treasury bet linked to Ethereum. ...